Sosei Group Corp., of Tokyo, said its partner, Genentech Inc., a member of the Roche Group, of Basel, Switzerland, plans to select a new G protein-coupled receptor, or GPCR, disease target, which triggered a $3 million payment to Sosei Heptares.
Even as the U.S. House of Representatives fast tracks H.R. 3, the Lower Drug Costs Now Act, as its solution to making prescription drugs more affordable, other bills aimed at drug pricing continue to roll in.
After proposing an undisclosed alternative price, Clovis Oncology Inc., of Boulder, Colo., got the approval of the U.K.'s National Institute for Health and Care Excellence (NICE) for coverage of its ovarian cancer drug Rubraca (rucaparib) under the Cancer Drugs Fund (CDF) while the company continues to collect long-term overall survival data.
The Institute for Clinical and Economic Review (ICER), of Boston, said it released an updated draft evidence report assessing the comparative clinical effectiveness and value of treatments for rheumatoid arthritis.
The FDA’s Office of Pediatric Therapeutics will hold a public workshop at the agency’s Silver Springs, Md., campus Nov. 12 to discuss pediatric patient-specific engagement in the development of clinical trial endpoints for rare diseases.
Galderma Pharma SA, of Lausanne, Switzerland, received a manufacturing license from the Swedish Medical Products Agency for a facility in Uppsala, Sweden. The facility will manufacture Galderma's QM-1114, a botulinum toxin derived from a strain of Clostridium botulinum.
President Donald Trump signed two executive orders Wednesday to improve transparency and fairness in U.S. government agencies and to ensure that they are held accountable.
RSS